Spectrum™



SV Spectrum™:

a compendium of evidence

Providing proven protection against CRBSIs.[1]

SV SPECTRUM™ CATHETERS meet the **CDC 1A RECOMMENDATION** as a component of the prevention of CLABSIs.[2]

1. Raad I, Darouiche R, Dupuis J, et al. Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections: a randomized, double-blind trial. *Ann Intern Med.* 1997;127(4):267-274.

2. O'Grady NP, Alexander M, Burns LA, et al. Guidelines for the prevention of intravascular catheter-related infections, 2011. Centers for Disease Control and Prevention website. www.cdc.gov/infectioncontrol/pdf/guidelines/bsi-guidelines.pdf. Updated February 15, 2017. Accessed July 6, 2017. The 1A recommendation from the Centers for Disease Control and Prevention (CDC) is to "Use a chlorhexidine/silver sulfadiazine or minocycline/rifampin -impregnated CVC in patients whose catheter is expected to remain in place >5 days if, after successful implementation of a comprehensive strategy to reduce rates of CLABSI, the CLABSI rate is not decreasing."

SPECTRUM VASCULAR™

Spectrum™

Providing proven protection against CRBSIs.[1]

The science and efficacy of minocycline + rifampin catheters.

This compendium of studies organizes the vast body of research investigating and supporting SV Spectrum™ into manageable sections that are easy to understand and quickly reference.

If you require any additional resources, please contact your Spectrum Vascular sales representative.

To learn more about SV Spectrum™ technology, visit **spectrumvascular.com**.

1. Raad I, Darouiche R, Dupuis J, et al. Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections: a randomized, double-blind trial. *Ann Intern Med.* 1997;127(4):267-274.

Spectrum™

SV Spectrum™ efficacy

1. **Effectiveness of minocycline and rifampin vs chlorhexidine and silver sulfadiazine-impregnated central venous catheters in preventing central line-associated bloodstream infection in a high-volume academic intensive care unit: a before and after trial.**
   Bonne S, Mazuski JE, Sona C, et al.
   Journal of the American College of Surgeons. 2015;221(3):739-747.
   ncbi.nlm.nih.gov/pubmed/26199017

2. **Novel approach using antimicrobial catheters to improve the management of central line-associated bloodstream infections in cancer patients.**
   Chaftari A, Kassis C, El Issa H, et al.
   Cancer. 2011;117(11):2551-2558.
   onlinelibrary.wiley.com/doi/10.1002/cncr.25807/full

3. **The clinical effectiveness of central venous catheters treated with anti-infective agents in preventing catheter-related bloodstream infections: a systematic review.**
   Hockenhull JC, Dwan KM, Smith GW, et al.
   Critical Care Medicine. 2009;37(2):702-712.
   ncbi.nlm.nih.gov/pubmed/19114884

4. **A systematic review comparing the relative effectiveness of antimicrobial-coated catheters in intensive care units.**
   Ramritu P, Halton K, Collignon P, et al.
   American Journal of Infection Control. 2008;36(2):104-117.
   ncbi.nlm.nih.gov/pubmed/18313512

5. **Antimicrobial central venous catheters in adults: a systematic review and meta-analysis.**
   Casey AL, Mermel LA, Nightingale P, et al.
   The Lancet Infectious Diseases. 2008;8(12):763-776.
   ncbi.nlm.nih.gov/pubmed/19022192

6. **Effectiveness of impregnated central venous catheters for catheter related blood stream infection: a systematic review.**
   Gilbert RE, Harden M.
   Current Opinion in Infectious Diseases. 2008;21(3):235-245.
   ncbi.nlm.nih.gov/pubmed/18448967

7. **Rifampicin-impregnated central venous catheters: a meta-analysis of randomized controlled trials.**
   Falagas ME, Fragoulis K, Bliziotis IA, et al.
   Journal of Antimicrobial Chemotherapy. 2007;59(3):359-369.
   jac.oxfordjournals.org/content/59/3/359.full

8. **Comparative in vitro efficacies and antimicrobial durabilities of novel antimicrobial central venous catheters.**
   Hanna H, Bahna P, Reitzel R, et al.
   Antimicrobial Agents and Chemotherapy. 2006;50(10):3283-3288.
   ncbi.nlm.nih.gov/pmc/articles/PMC1610097

9. **Vancomycin-resistant organisms on a burn unit.**
Still J, Law E, Friedman B, et al.
Southern Medical Journal. 2001;94(8):810-812.
ncbi.nlm.nih.gov/pubmed/11549193

10. **A comparison of two antimicrobial-impregnated central venous catheters.**
Darouiche RO, Raad II, Heard SO, et al.
New England Journal of Medicine. 1999;340(1):1-8.
nejm.org/doi/full/10.1056/NEJM199901073400101

11. **The evolving technology of venous access.**
Wenzel RP, Edmond MB.
New England Journal of Medicine. 1999;340(1):48-50.
ncbi.nlm.nih.gov/pubmed/9878645

12. **The ex vivo antimicrobial activity and colonization rate of two antimicrobial-bonded central venous catheters.**
Marik PE, Abraham G, Careau P, et al.
Critical Care Medicine. 1999;27(6):1128-1131.
ncbi.nlm.nih.gov/pubmed/10397217

13. **Antimicrobial durability and rare ultrastructural colonization of indwelling central catheters coated with minocycline and rifampin.**
Raad I, Darouiche RO, Hachem R, et al.
Critical Care Medicine. 1998;26(2):219-224.
ncbi.nlm.nih.gov/pubmed/9468157

14. **Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections: a randomized, double-blind trial.**
Raad I, Darouiche R, Dupuis J, et al.
Annals of Internal Medicine. 1997;127(4):267-274.
annals.org/article.aspx?articleid=710759

SV Spectrum™ science

15. **Anti-adherence activity and antimicrobial durability of anti-infective coated catheters against multidrug-resistant bacteria.**
Raad I, Reitzel R, Jiang Y, et al.
Journal of Antimicrobial Chemotherapy. 2008;62(4):746-750.
jac.oxfordjournals.org/content/62/4/746

16. **The broad-spectrum activity and efficacy of catheters coated with minocycline and rifampin.**
Raad I, Darouiche R, Hachem R, et al.
The Journal of Infectious Diseases. 1996;173(2):418-424.
jstor.org/stable/30126138

17. **Antibiotics and prevention of microbial colonization of catheters.**
Raad I, Darouiche R, Hachem R, et al.
Antimicrobial Agents and Chemotherapy. 1995;39(11):2397-2400.
ncbi.nlm.nih.gov/pmc/articles/PMC162954

18. **Antibiotic susceptibility of staphylococcal isolates from patients with vascular catheter-related bacteremia: potential role of the combination of minocycline and rifampin.**
Darouiche RO, Raad II, Bodey GP, et al.
International Journal of Antimicrobial Agents. 1995;6(1):31-36.
ncbi.nlm.nih.gov/pubmed/18611682

SV Spectrum™ cost effectiveness

19. **Attributable cost of catheter-associated bloodstream infections among intensive care patients in a nonteaching hospital.**
Warren DK, Quadir WW, Hollenbeak CS, et al.
Critical Care Medicine. 2006;34(8):2084-2089.
ncbi.nlm.nih.gov/pubmed/16763511

20. **Evidence that prevention makes cents: costs of catheter-associated bloodstream infections in the intensive care unit.**
Cosgrove SE.
Critical Care Medicine. 2006;34(8):2243-2244.
ncbi.nlm.nih.gov/pubmed/16883193

21. **Antibiotic-impregnated catheters associated with significant decrease in nosocomial and multidrug-resistant bacteremias in critically ill patients.**
Hanna HA, Raad II, Hackett B, et al.
Chest. 2003;124(3):1030-1038.
ncbi.nlm.nih.gov/pubmed/12970034

22. **New choices for central venous catheters: potential financial implications.**
Shorr AF, Humphreys CW, Helman DL.
Chest. 2003;124(1):275-284.
ncbi.nlm.nih.gov/pubmed/12853534

23. **Which antimicrobial impregnated central venous catheter should we use? Modeling the costs and outcomes of antimicrobial catheter use.**
Marciante KD, Veenstra DL, Lipsky BA, et al.
American Journal of Infection Control. 2003;31(1):1-8.
ncbi.nlm.nih.gov/pubmed/12548250

24. **Making health care safer: a critical analysis of patient safety practices.**
Shojania KG, Duncan BW, McDonald KM, et al.
Evidence Report/Technology Assessment Summary. 2001;(43):1-12.
ncbi.nlm.nih.gov/pubmed/11510252

SV Spectrum™ and antibiotic resistance

25. **Clinical effectiveness and risk of emerging resistance associated with prolonged use of antibiotic-impregnated catheters: more than 0.5 million catheter days and 7 years of clinical experience.**
Ramos ER, Reitzel R, Jiang Y, et al.
Critical Care Medicine. 2011;39(2):245-251.
ncbi.nlm.nih.gov/pubmed/21057308

26. **Clinical experience with minocycline and rifampin-impregnated central venous catheters in bone marrow transplantation recipients: efficacy and low risk of developing staphylococcal resistance.**
Chatzinikolaou I, Hanna H, Graviss L, et al.
Infection Control and Hospital Epidemiology. 2003;24(12):961-963.
ncbi.nlm.nih.gov/pubmed/14700414

27. **New technology for reducing infection and resistance in the ICU.**
Crnich CJ, Maki DG.
The Journal of Critical Illness. 2002;17:48-51.
business.highbeam.com/4312/article-1G1-83373440/new-technology-reducing-infection-and-resistance-icu

28. **Comparison of an untreated vs. silver/chlorhexidine vs. rifampin/minocycline central venous catheter in reducing catheter-related bloodstream infections.**
Brooks K, Dauenhauer S, Nelson M.
Abstract presented at: APIC 28th Annual Educational Conference and International Meeting; June 10-14, 2001; Seattle, WA.
No online source.

SV Spectrum™ long-term silicone

29. **Comparison of antimicrobial impregnation with tunneling of long-term central venous catheters: a randomized controlled trial.**
Darouiche RO, Berger DH, Khardori N, et al.
Annals of Surgery. 2005;242(2):193-200.
ncbi.nlm.nih.gov/pmc/articles/PMC1357724

30. **Long-term silicone central venous catheters impregnated with minocycline and rifampin decrease rates of catheter-related bloodstream infection in cancer patients: a prospective randomized clinical trial.**
Hanna H, Benjamin R, Chatzinikolaou I, et al.
Journal of Clinical Oncology. 2004;22(15):3163-3171.
ncbi.nlm.nih.gov/pubmed/15284269

Spectrum™

RISK INFORMATION

For important product safety information, please refer to the product specific Instructions for Use (IFUs) and/or User Manual provided with the product for any Instructions, Warnings, Indications, Precautions, Potential Adverse Effects, Contraindications and Cautions.

CAUTION

Federal law (USA) restricts these devices to sale by or on the order of a physician.

SPECTRUM VASCULAR™

www.spectrumvascular.com